Identifying and selecting the right sites and investigators is of paramount importance for a successful, timely and cost-efficient execution of a clinical trial. Despite their great importance, the tools available to facilitate these critical tasks are inefficient, siloed and expensive. A new approach is needed, especially with regard to investigator selection.
Find relevant investigators and affiliated sites in seconds that meet your study-specific requirements based on highly targeted characteristics, such as geographic location, historic trial involvement and performance, industry collaborations, research output and much more.
Prioritize among investigators, physicians and sites based on trial track record, industry involvement, collaboration network, research relevance, maturity and more. Proprietary ranking algorithms ensure that you always look at relevant stakeholders and relevant research activities.
Build stronger relationships and drive critical engagement through collaborative user work spaces, continuous scientific and clinical activity notifications, proactive relationship analysis, advanced export capabilities, project folders for drug programs, panels, therapy areas and much more.
Experience a platform built to improve clinical trial feasibility. Our attention to detail and end user value have pushed the industry standard. Further increase your efficiency and business performance through custom integrations with other solutions, including individual trial repositories.
“Monocl has truly transformed the way we work with identification of investigators, sites and research clusters to support our development pipeline.”- Site Feasibility Manager, Big Pharma, US
One of the world’s largest pharma companies has used Monocl globally for investigator and site selection since 2016. A key reason for their satisfaction is that they are able to identify highly relevant investigators and sites anywhere in the world for any therapy areas of interest, further qualified by targets, drug classes, technologies and much more. As each investigator profile also contains research publications, grants and industry funding and more, a new and much deeper holistic understanding is possible. The overall approach has been very effective for the oncology teams responsible for investigator selection, site feasibility and clinical intelligence.
In a novel effort to broaden its base of potential investigators to collaborate with in a range of rare diseases, a global Big Pharma company used Monocl to systematically evaluate physicians who were proficient in specific rare diseases but had little or no previous clinical trial experience. Based on the results generated, a range of physicians were approached and those who were interested underwent GCP training and other necessary training to be eligible to run and/or participate in clinical trials. The project resulted in a subsequent expansion to additional therapy areas.
Reach out directly for a demo.